阿尔茨海默病相关血液学标志物研究进展

doi:10.3969/j.issn.1673-8640.2020.04.019

摘要/Abstract

摘要：

阿尔茨海默病（AD）是一种中枢神经系统退行性疾病,主要临床表现为记忆、认知障碍以及后期的人格和行为改变等。有很多血液学指标和AD密切相关,如蛋白质、基因突变、微小RNA（miRNA）等,或可用于预测AD发生风险、反映疾病阶段及支持AD诊断。血液学标志物的检测简便、易行,因此,筛选理想的AD相关血液学标志物有利于AD的筛查与治疗。文章总结了AD相关血液学标志物的研究现状,并讨论其应用于临床的可能性和局限性。

关键词: 血液学标志物, 阿尔茨海默病, 筛查, 诊断

Abstract:

Alzheimer's disease（AD）is a degenerative disease of the central nervous system with clinical manifestations of memory impairment,cognitive impairment,later personality and behavioral changes. Recently,studies have shown that many blood markers are closely related to AD,like protein,gene mutation,microRNA（miRNA）,which may play a certain role in predicting the risk of AD,reflecting the stage of AD and supporting the diagnosis of AD. In addition,the determination method of blood markers is simple and easy,therefore screening ideal AD-related blood markers is beneficial to the screening and treatment of AD. In this review,the latest research status of AD-related blood markers is summarized,and the possibility and limitation of its clinical application are discussed.

Key words: Blood marker, Alzheimer's disease, Screening, Diagnosis

中图分类号:

R446.1

陈小童, 林勇. 阿尔茨海默病相关血液学标志物研究进展[J]. 检验医学, 2020, 35(4): 374-379.

CHEN Xiaotong, LIN Yong. Progressive research of Alzheimer's disease-related blood markers[J]. Laboratory Medicine, 2020, 35(4): 374-379.

参考文献 50.

1.	SUGINO H,WATANABE A,AMADA N,et al.Global trends in alzheimer disease clinical development:increasing the probability of success[J]. Clin Ther,2015,37(8):1632-1642.
2.	FRICKER M,TOLKOVSKY A M,BORUTAITE V,et al.Neuronal cell death[J]. Physiol Rev,2018,98(2):813-880.
3.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Research criteria for the diagnosis of Alzheimer's disease:revising the NINCDS-ADRDA criteria[J]. Lancet Neurol,2007,6(8):734-746.
4.	DUBOIS B,FELDMAN H H,JACOVA C,et al.Advancing research diagnostic criteria for Alzheimer's disease:the IWG-2 criteria[J]. Lancet Neurol,2014,13(6):614-629.
5.	JACK C R Jr,BENNETT D A,BLENNOW K,et al. NIA-AA research framework:toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement,2018,14(4):535-562.
6.	JAGUST W.Imaging the evolution and pathophysiology of Alzheimer disease[J]. Nat Rev Neurosci,2018,19(11):687-700.
7.	SCHELTENS P,BLENNOW K,BRETELER M M,et al.Alzheimer's disease[J]. Lancet,2016,388(10043):505-517.
8.	WANG J,GU B J,MASTERS C L,et al.A systemic view of Alzheimer disease-insights from amyloid-β metabolism beyond the brain[J]. Nat Rev Neurol,2017,13(10):612-623.
9.	VERBERK I M W,SLOT R E,VERFAILLIE S C J,et al. Plasma amyloid as prescreener for the earliest Alzheimer pathological changes[J]. Ann Neurol,2018,84(5):648-658.
10.	NAKAMURA A,KANEKO N,VILLEMAGNE V L,et al.High performance plasma amyloid-β biomarkers for Alzheimer's disease[J]. Nature,2018,554(7691):249-254.
11.	NABERS A,PERNA L,LANGE J,et al.Amyloid blood biomarker detects Alzheimer's disease[J]. EMBO Mol Med,2018,10(5).
12.	VARMA V R,OOMMEN A M,VARMA S,et al.Brain and blood metabolite signatures of pathology and progression in Alzheimer disease:a targeted metabolomics study[J]. PLoS Med,2018,15(1):e1002482.
13.	SHEN Y,WANG H,SUN Q,et al.Increased plasma beta-secretase 1 may predict conversion to Alzheimer's disease dementia in individuals with mild cognitive impairment[J]. Biol Psych,2018,83(5):447-455.
14.	PEÑA-BAUTISTA C,VIGOR C,GALANO J M,et al. Plasma lipid peroxidation biomarkers for early and non-invasive Alzheimer disease detection[J]. Free Radic Biol Med,2018,124:388-394.
15.	TROUGAKOS I P.The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress:implications in therapeutic approaches-a mini-review[J]. Gerontology,2013,59(6):514-523.
16.	PERROTTE M,LE PAGE A,FOURNET M,et al.Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimer's disease patients[J]. Free Radic Biol Med,2019,130:499-511.
17.	PADURARIU M,CIOBICA A,HRITCU L,et al.Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease[J]. Neurosci Lett,2010,469(1):6-10.
18.	HEPPNER F L,RANSOHOFF R M,BECHER B.Immune attack:the role of inflammation in Alzheimer disease[J]. Nat Rev Neurosci,2015,16(6):358-372.
19.	HENEKA M T,GOLENBOCK D T,LATZ E.Innate immunity in Alzheimer's disease[J]. Nat Immunol,2015,16(3):229-236.
20.	FORLENZA O V,DINIZ B S,TALIB L L,et al.Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment[J]. Dement Geriatr Cogn Disord,2009,28(6):507-512.
21.	HARDY J,SELKOE D J.The amyloid hypothesis of Alzheimer's disease:progress and problems on the road to therapeutics[J]. Science,2002,297(5580):353-356.
22.	HEILIG E A,XIA W,SHEN J,et al.A presenilin-1 mutation identified in familial Alzheimer disease with cotton wool plaques causes a nearly complete loss of gamma-secretase activity[J]. J Biol Chem,2010,285(29):22350-22359.
23.	VEUGELEN S,SAITO T,SAIDO T C,et al.Familial Alzheimer's disease mutations in presenilin generate amyloidogenic Aβ peptide seeds[J]. Neuron,2016,90(2):410-416.
24.	WANG Y,MANDELKOW E.Tau in physiology and pathology[J]. Nat Rev Neurosci,2016,17(1):5-21.
25.	MIELKE M M,HAGEN C E,XU J,et al.Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography[J]. Alzheimers Dement,2018,14(8):989-997.
26.	OLSSON B,LAUTNER R,ANDREASSON U,et al.CSF and blood biomarkers for the diagnosis of Alzheimer's disease:a systematic review and meta-analysis[J]. Lancet Neurol,2016,15(7):673-684.
27.	CORSI M M,LICASTRO F,PORCELLINI E,et al.Reduced plasma levels of P-selectin and L-selectin in a pilot study from Alzheimer disease:relationship with neuro-degeneration[J]. Biogerontology,2011,12(5):451-454.
28.	丁冰玉,林萍,李擎天. 植物血凝素刺激外周血单个核细胞Th1/Th2细胞因子分泌对阿尔茨海默病的诊断价值[J]. 检验医学,2018,33(4):290-294.
29.	D'ANNA L,ABU-RUMEILEH S,FABRIS M,et al. Serum interleukin-10 levels correlate with cerebrospinal fluid amyloid beta deposition in Alzheimer disease patients[J]. Neurodegener Dis,2017,17(4-5):227-234.
30.	TOGO T,AKIYAMA H,KONDO H,et al.Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases[J]. Brain Res,2000,885(1):117-121.
31.	MOCALI A,CEDROLA S,DELLA MALVA N,et al.Increased plasma levels of soluble CD40,together with the decrease of TGF beta 1,as possible differential markers of Alzheimer disease[J]. Exp Gerontol,2004,39(10):1555-1561.
32.	BROSSERON F,KRAUTHAUSEN M,KUMMER M,et al.Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease:a comparative overview[J]. Mol Neurobiol,2014,50(2):534-544.
33.	TRAMUTOLA A,ABATE G,LANZILLOTTA C,et al.Protein nitration profile of CD3+:lymphocytes from Alzheimer disease patients:novel hints on immunosenescence and biomarker detection[J]. Free Radic Biol Med,2018,129:430-439.
34.	BHATNAGAR S,CHERTKOW H,SCHIPPER H M,et al.Increased microRNA-34c abundance in Alzheimer's disease circulating blood plasma[J]. Front Mol Neurosci,2014,7:2.
35.	AYBEK H,ERCAN F,ASLAN D,et al.Determination of malondialdehyde,reduced glutathione levels and APOE4 allele frequency in late-onset Alzheimer's disease in Denizli,Turkey[J]. Clin Biochem,2007,40(3-4):172-176.
36.	FIANDACA M S,KAPOGIANNIS D,MAPSTONE M,et al.Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes:a case-control study[J]. Alzheimers Dement,2015,11(6):600-607.e1.
37.	HARA N,KIKUCHI M,MIYASHITA A,et al.Serum microRNA miR-501-3p as a potential biomarker related to the progression of Alzheimer's disease[J]. Acta Neuropathol Commun,2017,5(1):10.
38.	YANG T T,LIU C G,GAO S C,et al.The serum exosome derived microRNA-135a,-193b,and -384 were potential Alzheimer's disease biomarkers[J]. Biomed Environ Sci,2018,31(2):87-96.
39.	HONG S,BEJA-GLASSER V FNFONOYIM B M,et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models[J]. Science,2016,352(6286):712-716.
40.	ZHOU X,CHEN Y,MOK K Y,et al.Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer's disease pathogenesis[J]. Proc Natl Acad Sci U S A,2018,115(8):1697-1706.
41.	WENDELN A C,DEGENHARDT K,KAURANI L,et al.Innate immune memory in the brain shapes neurological disease hallmarks[J]. Nature,2018,556(7701):332-338.
42.	SNYDER H M,CARRILLO M C,GRODSTEIN F,et al.Developing novel blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):109-114.
43.	FIORINI M,BONGIANNI M,BENEDETTI M D,et al.Reappraisal of Aβ40 and Aβ42 peptides measurements in cerebrospinal fluid of patients with Alzheimer's disease[J]. J Alzheimers Dis,2018,66(1):219-227.
44.	SWEENEY M D,SAGARE A P,ZLOKOVIC B V.Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders[J]. Nat Rev Neurol,2018,14(3):133-150.
45.	HENRIKSEN K,O'BRYANT S E,HAMPEL H,et al. The future of blood-based biomarkers for Alzheimer's disease[J]. Alzheimers Dement,2014,10(1):115-131.
46.	THAMBISETTY M,LOVESTONE S.Blood-based biomarkers of Alzheimer's disease:challenging but feasible[J]. Biomark Med,2010,4(1):65-79.
47.	O'BRYANT S E,EDWARDS M,JOHNSON L,et al. A blood screening test for Alzheimer's disease[J]. Alzheimer's Dementia(Amst),2016,3:83-90.
48.	WOOD H.Alzheimer disease:localized proteomics distinguishes AD subtypes[J]. Nat Rev Neurol,2017,13(5):260.
49.	ROSENBERG R N,LAMBRACHT-WASHINGTON D,YU G,et al.Genomics of Alzheimer disease:a review[J]. JAMA Neurol,2016,73(7):867-874.
50.	XIANG Y,LAM S M,SHUI G.What can lipidomics tell us about the pathogenesis of Alzheimer disease?[J]. Biol Chem,2015,396(12):1281-1291.

[1]	上海中医药大学附属岳阳中西医结合医院上海市临床检验中心, 中国康复医学会医学检验与康复专业委员会中国中西医结合学会检验医学专业委员会, 上海市免疫学会肿瘤免疫分会上海市医学会分子诊断专科分会. 肝纤维化非创伤性实验诊断专家共识[J]. 检验医学, 2025, 40(7): 625-641.
[2]	吴钧, 陶月, 陈德柱, 沙娇娇, 杜靓佳, 陈衣强, 刘思远, 宋宏岩, 郑茜, 柏兵. 不同脑部疾病患者尿液AD7c-NTP阳性率分析[J]. 检验医学, 2025, 40(7): 642-647.
[3]	夏远志, 尹向飞, 林斯恩, 梁小亮. 基于Meta分析评估BoBs技术在染色体非整倍体异常产前诊断中的价值[J]. 检验医学, 2025, 40(5): 477-483.
[4]	张国英, 陆忠奎, 王裕玲, 夏厦, 孟轲, 何芳, 黄子慧, 杨增敏, 刘欣. γ-干扰素诱导蛋白-10 mRNA检测技术在肺外结核病诊断中的应用[J]. 检验医学, 2025, 40(4): 372-376.
[5]	康俞莉, 李莉, 陈果, 王艺静, 张立, 章强强, 赵颖. 播散性隐球菌病病例分析[J]. 检验医学, 2025, 40(4): 393-399.
[6]	翁文浩. 儿童自身免疫性疾病实验室诊断和免疫调节机制研究进展[J]. 检验医学, 2025, 40(3): 205-208.
[7]	马展, 翁文浩. 儿童自身免疫性肝病及其实验室诊断进展[J]. 检验医学, 2025, 40(3): 218-222.
[8]	余佳杰, 张智智, 罗清琼, 柯星. 基于多种血清肿瘤标志物的深度学习模型用于评估早期结直肠肿瘤患病风险[J]. 检验医学, 2025, 40(3): 253-258.
[9]	王彬彬, 李凤启, 郭凤莲, 张蕊, 康慧慧, 王岳彤. SF3B4基因新变异致Nager型肢面骨发育不良1型新生儿临床特征和遗传学分析[J]. 检验医学, 2025, 40(2): 142-147.
[10]	王成云, 顾萍, 潘秋辉, 王静. 感染患儿凝血相关指标的变化及其临床意义[J]. 检验医学, 2025, 40(2): 178-181.
[11]	史健, 雷静, 耿燕. 宏基因组二代测序在肺部感染诊断中的应用价值[J]. 检验医学, 2025, 40(12): 1232-1236.
[12]	季雄娟, 陆胜, 周卫平. 血小板抗体形成影响因素分析[J]. 检验医学, 2025, 40(11): 1102-1104.
[13]	徐贲, 冯章亮, 宋小军, 金大智, 陈毓. 呼吸道感染病原学分子诊断技术研究进展[J]. 检验医学, 2025, 40(10): 1019-1024.
[14]	罗静, 袁佳仪, 姚小艳, 范列英. RA患者外周血单核细胞亚型中组织蛋白酶C表达的变化[J]. 检验医学, 2025, 40(10): 933-940.
[15]	丁静, 李会丹, 张春玲, 王小蕊, 刘伟玲, 蔺丽慧, 邱慧颖. 基于不同分类标准的髓系肿瘤实验室诊断及预后相关因素分析[J]. 检验医学, 2025, 40(1): 25-31.